תזונה ותוספים Vitamin D supplementation in institutionalized elderly. Effects of vitamin D3 (100,00

[Mike Bikov]

Rev Rhum Mal Osteoartic. 1990 Nov;57(11):809-13.Links
[Vitamin D supplementation in institutionalized elderly. Effects of vitamin D3 (100,000 IU) orally administered every 3 months on serum levels of 25-hydroxyvitamin D]
[Article in French]

Zeghoud F, Jardel A, Garabedian M, Salvatore R, Moulias R.

C.N.R.S. URA 583, Université Paris V, Hôpital Necker, Paris.

A clinical trial carried out during the autumn/winter season in 46 institutionalized elderly subjects (35 women, 11 men) (group mean age = 83 +/- 2 years) revealed a severe deficiency in vitamin D in these subjects (25-hydroxyvitamin D level less than or equal to 3 ng/ml). After oral administration of 100,000 IU of vitamin D3, an increase in 25-hydroxyvitamin D levels above the 10 ng/ml threshold was observed and maintained for three months. A second dose, administered after 3 months, made it possible to sustain this level. No sign of toxicity was detected, notably no trace of hypercalcemia. In contrast, no change in the deficit (25-hydroxyvitamin D level less than or equal to 3 ng/ml) was seen in the placebo population. Three-monthly administration of the moderate dosage of 100,000 IU of vitamin D3 all year round would offer a simple, effective and risk-free system to counteract vitamin D deficiency in the elderly and of preventing the risk of osteomalacia, thus reducing the incidence of fractures.​

🤡🤡

 

[Mike Bikov]

Am J Clin Nutr. 2008 Mar;87(3):688-91.Click here to read Links
Pharmacokinetics of a single, large dose of cholecalciferol.
Ilahi M, Armas LA, Heaney RP.

Creighton University Medical Center, Omaha, NE 68131, USA.

BACKGROUND: There is much interest in dosing vitamin D intermittently for patient convenience and long-term adherence. OBJECTIVE: The objective was to characterize the time course and response of 25-hydroxyvitamin D (calcidiol) to a large oral dose of cholecalciferol. DESIGN: One group (30 subjects) was supplemented with a single oral dose of 100,000 IU cholecalciferol. A second group (10 subjects) served as a control group to assess the seasonal change of calcidiol. Serum calcidiol concentrations were followed for 4 mo. The subjects were healthy with limited sun exposure (<10 h/wk) and milk consumption (<0.47 L daily). We excluded subjects with granulomatous conditions, liver disease, kidney disease, or diabetes and subjects taking anticonvulsants, barbiturates, or steroids. RESULTS: Serum calcidiol rose promptly after cholecalciferol dosing from a mean (+/-SD) baseline of 27.1 +/- 7.7 ng/mL to a concentration maximum of 42.0 +/- 9.1 ng/mL. Seven percent of the supplemented cohort failed to achieve 32.1 ng/mL at any time point. The highest achieved concentration in any subject was 64.2 ng/mL. The control group had a nonsignificant change from baseline of -0.72 +/- 0.80 ng/mL during 4 mo. CONCLUSIONS: Cholecalciferol (100,000 IU) is a safe, effective, and simple way to increase calcidiol concentrations. The dosing interval should be < or =2 mo to ensure continuous serum calcidiol concentrations above baseline. This trial was registered at www.clinicaltrials.gov as #NCT00473239.

....​